N/A N=76 Bard® LifeStent® Vascular Stent Delivery System Study
Peripheral Vascular Disease
Primary: Acute Effectiveness: Percentage of Stents With Successful Delivery — 100 percentage of stents
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=122 Effect of Oseltamivir on Cognitive Function in Subjects With Influenza
Influenza
Primary: Change in Attention Assessment — -70.0; -39.7 milliseconds — p=.0492
Phase 2 N=126 An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured…
Phase 4 N=40 A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
Colorectal Cancer
Primary: Percentage of Participants With Adverse Events — 100 percentage of participants
Phase 3 N=44 An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures
Epilepsy · Generalized Tonic-clonic Seizures
Primary: Incidence of Treatment Emergent Adverse Events During the Entire Study Period — 626 Treatment Emergent Adverse Events
Phase 3 N=356 Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
Influenza
Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies Titers Against the 4 Vaccine Strains. — 253.2; 235.5; 73.6; 78.6 Titers
N/A N=152 Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Ankylosing Spondylitis
Primary: Percentage of Participants With Unchanged First Line Anti-TNF Treatment Up to Month 18 — 85.42 percentage of participants
Phase 4 N=13 The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 3; 8 Participants
N/A N=154 Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients
Diabetes Mellitus Type 2
Primary: Reduction in HbA1c — -0.52; -0.14 % (unit of HbA1c)
Phase 2 N=20 Multi-day Doses in Prevention of Nausea and Emesis
Myeloma, Plasma-Cell · Lymphoma, Malignant
Primary: Overall Emetic Response: Acute — 5; 9; 1; 0 Participants
Phase 4 N=18 Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 0; 17 Participants
N/A N=248 AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use
Vascular Access Complication
Primary: First Attempt Success Rate With Peripheral IV Catheter Placement — 89; 47 percentage of participants — p=<0.0001
N/A N=76 Carestream Digital Radiography Long Length Imaging Software Data Collection Protocol
Spinal Injuries
Primary: Radlex Scale for Diagnostic Capability Ratings - Cedara Accustitch Software (Predicate) — 3.01 units on a scale — p=0.02
N/A N=30 A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients
Immunosuppression
Primary: GI Side Effects as Assessed by Gastro Intestinal Symptoms Rating Scale (GSRS) of Enteric-coated Mycophenolate Sodium vs Mycophenolate Mofetil — 21.80; 23.07; 24.90…
Phase 3 N=289 Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Change in Pain Intensity — 3.56; 3.26; 3.07; 2.90 Units on a scale — p=<.001